Skip to content
Disclosery

EXANE DERIVATIVES: FELE position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on FELE, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 2,850 FELE shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 2,850 shares
    Change vs previous 13F +405 shares

    0.12% of the 13F portfolio, value $208,748.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 2,445 shares
    Change vs previous 13F -475 shares

    0.06% of the 13F portfolio, value $203,020.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 2,920 shares
    Change vs previous 13F +78 shares

    0.07% of the 13F portfolio, value $276,105.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 2,842 shares
    Change vs previous 13F +386 shares

    0.06% of the 13F portfolio, value $226,926.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 2,456 shares
    Change vs previous 13F not available

    0.05% of the 13F portfolio, value $197,605.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).